Fig 1.
ICI: immune checkpoint inhibitors, irAE: immune-related adverse event.
Table 1.
Baseline characteristics of the patients in the study.
Fig 2.
Flow diagram of irAE resumption.
ICI: immune checkpoint inhibitors, irAE: immune-related adverse event.
Table 2.
Clinical courses of patients with recurring grade ≥2 irAEs after ICI resumption.
Table 3.
Factors associated with the recurrence of grade ≥2 irAEs after ICI resumption.